Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...

EAI-432, an allosteric inhibitor, offers a new approach to targeting mutant-EGFR driven NSCLC By binding outside the ATP pocket, it co-binds with the current standard-of-care third generation EGFR ...

Treatment pattern and outcomes in patients with uncommon or compound EGFR mutations in India: CRSF 2020-03 study. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract ...

Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...

The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events than standard therapy.

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...

Effect of IKKϵ knock-down on prostate cancer xenograft growth. Background: Activating EGFR mutations have become a backbone in the therapy alogrithm for NSCLC as mutations predict significantly better ...

In a recent study published in Micromachines, researchers assessed the efficiency of a genetic decoding system for diagnosing non-small cell lung cancer (NSCLC). Study: Intelligent Genetic Decoding ...

Current treatment guidelines recommend that mNSCLC patients should be tested for actionable mutations to help guide appropriate first-line treatment options. 7 “In patients with mNSCLC of ...